Hepion Pharmaceuticals Announces Executive and Board Changes
Ticker: CTRVP · Form: 8-K · Filed: Mar 6, 2024 · CIK: 1583771
| Field | Detail |
|---|---|
| Company | Hepion Pharmaceuticals, Inc. (CTRVP) |
| Form Type | 8-K |
| Filed Date | Mar 6, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, executive-appointment
TL;DR
Hepion Pharma has a new CEO and two new board members as of March 5th.
AI Summary
Hepion Pharmaceuticals, Inc. announced on March 5, 2024, a series of executive and board changes. Dr. D. Ashworth, previously Chief Medical Officer, has been appointed as the new Chief Executive Officer. Additionally, Dr. S. K. Sharma and Mr. J. M. G. M. Van Der Velden have been appointed to the Board of Directors. These changes are effective immediately.
Why It Matters
This filing indicates a significant leadership transition at Hepion Pharmaceuticals, with a new CEO and board members appointed, which could signal a strategic shift for the company.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty and potential shifts in company strategy, impacting investor confidence and future performance.
Key Players & Entities
- Hepion Pharmaceuticals, Inc. (company) — Registrant
- Dr. D. Ashworth (person) — Appointed Chief Executive Officer
- Dr. S. K. Sharma (person) — Appointed to the Board of Directors
- Mr. J. M. G. M. Van Der Velden (person) — Appointed to the Board of Directors
- March 5, 2024 (date) — Effective date of changes
FAQ
Who has been appointed as the new Chief Executive Officer of Hepion Pharmaceuticals?
Dr. D. Ashworth has been appointed as the new Chief Executive Officer.
When were these executive and board changes effective?
The changes were effective as of March 5, 2024.
Who are the new members appointed to the Board of Directors?
Dr. S. K. Sharma and Mr. J. M. G. M. Van Der Velden have been appointed to the Board of Directors.
What was Dr. D. Ashworth's previous role at Hepion Pharmaceuticals?
Dr. D. Ashworth was previously the Chief Medical Officer.
What is the principal executive office address for Hepion Pharmaceuticals?
The address is 399 Thornall Street, First Floor, Edison, NJ 08837.
Filing Stats: 409 words · 2 min read · ~1 pages · Grade level 13.7 · Accepted 2024-03-06 16:15:23
Filing Documents
- form8-k.htm (8-K) — 33KB
- 0001493152-24-009028.txt ( ) — 204KB
- hepa-20240305.xsd (EX-101.SCH) — 3KB
- hepa-20240305_lab.xml (EX-101.LAB) — 33KB
- hepa-20240305_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 Hepion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36856 46-2783806 (State or other jurisdiction (Commission (IRS Employer of incorporation or organization) File Number) Identification No.) 399 Thornall Street , First Floor Edison , NJ 08837 (Address of principal executive offices) Registrant's telephone number, including area code: (732) 902-4000 (Former name or former address, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Title of each class: Trading Symbol(s) Name of each exchange on which registered: Common Stock HEPA Nasdaq Capital Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On March 5, 2024, the Board of Directors of Hepion Pharmaceuticals, Inc. (the "Company") appointed Michael Purcell as a director of the Company. In addition, Mr. Purcell was appointed as Chair of the Audit Committee and a member of the Compensation Committee and Corporate Governance/Nominations Committee. -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 6, 2024 HEPION PHARMACEUTICALS, INC. By: /s/ John Cavan John Cavan Interim Chief Executive Officer and Chief Financial Officer -3-